Filtered By:
Management: Funding

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 2110 results found since Jan 2013.

Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)
Notice NOT-DE-23-004 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 8, 2023 Category: Research Source Type: funding

Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!
Therapie. 2023 Feb 22:S0040-5957(23)00046-X. doi: 10.1016/j.therap.2023.02.009. Online ahead of print.ABSTRACTThe pandemic subsequent to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus resulted, for the French institutional pharmacovigilance, in a "health crisis" in 2 phases: the coronavirus disease 2019 - "COVID-19" phase during which the missions of the Regional Pharmacovigilance Centres (RPVC) were to detect a possible impact of drugs on this disease, as whether existed a possible aggravating role of certain drugs, or the safety profile of drugs used for the management of COVID-19 could evolve. Th...
Source: Therapie - March 8, 2023 Category: Psychiatry & Psychology Authors: Annie Pierre Jonville-Bera Sophie Gautier Jo ëlle Micallef Nathalie Massy Marina Atzenhoffer Milou-Daniel Drici Aur élie Grandvuillemin R éseau français des centres régionaux de pharmacovigilance Source Type: research

A research and development (R & amp;D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy
This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research cam...
Source: Vaccine - March 4, 2023 Category: Allergy & Immunology Authors: Kristine A Moore Tabitha Leighton Julia T Ostrowsky Cory J Anderson Richard N Danila Angela K Ulrich Eve M Lackritz Angela J Mehr Ralph S Baric Norman W Baylor Bruce G Gellin Jennifer L Gordon Florian Krammer Stanley Perlman Helen V Rees Melanie Saville C Source Type: research

Biden pushes for $1.6B funding for pandemic fraud measures
President Joe Biden's administration is starting a push to get Congress to fund measures to help prosecute fraud in government coronavirus pandemic relief programs
Source: ABC News: Health - March 2, 2023 Category: Consumer Health News Tags: Health Source Type: news

FY 2022 By the Numbers: Extramural Grant Investments in Research
Today we present our annual snapshot of NIH grant funding and success rate data for fiscal year (FY) 2022 enacted appropriations. These data are available in the NIH Data Book, which is also being regularly updated with other FY 2022 grants information. Similar to our FY 2021 and FY 2020 posts, spending related to special appropriations for coronavirus are excluded here, but may be found using RePORTER’s advanced search capabilities. In FY2022, NIH spent $33.3 billion of its total $45.2 billion appropriation for competing and noncompeting grant awards. This is a 3.1% increase (or $1.02 billion) in spending over the p...
Source: NIH Extramural Nexus - March 1, 2023 Category: Research Authors: Mike Lauer Tags: blog Open Mike awards grants Success Rate Source Type: funding

MRI for all: Cheap portable scanners aim to revolutionize medical imaging
.news-article__hero--featured .parallax__element{ object-position: 47% 50%; -o-object-position: 47% 50%; } The patient, a man in his 70s with a shock of silver hair, lies in the neuro intensive care unit (neuro ICU) at Yale New Haven Hospital. Looking at him, you’d never know that a few days earlier a tumor was removed from his pituitary gland. The operation didn’t leave a mark because, as is standard, surgeons reached the tumor through his nose. He chats cheerfully with a pair of research associates who have come to check his progress with a new and potentially revolutionary device they are testing. The cylind...
Source: Science of Aging Knowledge Environment - February 23, 2023 Category: Geriatrics Source Type: research

Gender Central to Parliamentarians ’ Programme of Action
Cooperative members in southern Lebanon make a rare, traditional bread called Mallet El Smid to be sold at the MENNA shop in Beirut. Women are central to meeting the SDGs, say parliamentarians. Credit: UN Women/Joe SaadeBy IPS CorrespondentJOHANNESBURG, Feb 23 2023 (IPS) The post-COVID-19 period has been a crucial one for members of parliament who have their work cut out to ensure that issues that arose during the pandemic are addressed, especially concerning the ICPD25 commitments and programmes of action for universal access to sexual and reproductive rights, gender-based violence and building peaceful, just and inclusiv...
Source: IPS Inter Press Service - Health - February 23, 2023 Category: International Medicine & Public Health Authors: IPS Correspondent Tags: Asia-Pacific COVID-19 Development & Aid Gender Gender Identity Gender Violence Middle East & North Africa TerraViva United Nations Women & Economy Women's Health Asian Population and Development Association (APDA) IPS UN Bureau IPS Source Type: news

Why Mississippi, a Covid Hot Spot, Left Millions in Pandemic Aid Unspent
Stop-and-go federal funding floods public health agencies with cash during crises but starves them of funds afterward. The coronavirus pandemic shows the pitfalls of that approach.
Source: NYT - February 13, 2023 Category: American Health Authors: Sharon LaFraniere Tags: Coronavirus (2019-nCoV) Mississippi States (US) Federal Budget (US) Centers for Disease Control and Prevention Budgets and Budgeting American Rescue Plan (2021) Medicine and Health Stimulus (Economic) CDC Foundation United States Polit Source Type: news

Japan moves to bolster vaccine R & D after COVID-19 exposed startling weakness
The COVID-19 pandemic exposed the feeble state of Japan’s vaccine research and development capabilities. Only now, for example, are Japanese regulators considering approval of the country’s first homegrown COVID-19 vaccines, months after many less advanced nations developed their own shots. Determined to catch up, Japan is ramping up a 1.1 trillion yen ($8.5 billion) initiative that aims to give Japan the capability to develop a vaccine for a new virus in 100 days, a goal being adopted by many countries. That “very ambitious” push “is definitely a welcome development,” especially given that it will give ne...
Source: Science of Aging Knowledge Environment - February 9, 2023 Category: Geriatrics Source Type: research

Pegylated interferon lambda
A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon. So starts the NYT article. Have we learned nothing? As for the drug itself, the news is good: …a new class of variant-proof treatments could help…#rainwaterfoundation #republicans
Source: Reuters: Health - February 9, 2023 Category: Consumer Health News Source Type: news

Why the Odds Are Stacked Against a Promising New Covid Drug
A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.
Source: NYT Health - February 8, 2023 Category: Consumer Health News Authors: Benjamin Mueller Tags: Coronavirus (2019-nCoV) Clinical Trials Research Regulation and Deregulation of Industry Interferon (Protein) Deaths (Fatalities) Paxlovid (Drug) your-feed-healthcare Source Type: news

Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news